SecBot SecBot

LLY drug pipeline

ELI LILLY & Co · 3 rated drugs
$1,443.50
+1.1% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±1.3%
1-day, median of 26 events
IV rank
20
IV 32% · HV 35%
Rated drugs
3
1 bullish · 2 mixed
Phase 3 trials
19
1 with results posted

Upcoming catalysts

4 dated
  1. Nov 2026
    tirzepatide
    Phase 3 primary completion
  2. Nov 2026
    tirzepatide
    Phase 3 primary completion
  3. Feb 2027
    Methylprednisolone
    Phase 2 primary completion
  4. Feb 2027
    Abemaciclib
    Phase 2 primary completion

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 2b completed; Phase 3 registered but not yet recruiting
Time to marketWith Phase 3 enrollment beginning in late 2026 and primary completion estimated around October 2029, followed by regulatory filing and review, a potential FDA approval is likely 4-6 years out, barring accelerated development.

EloraTZP eloralintide / tirzepatide combination Updated Oct 29

What to watch

Phase 3 trials AMPLIFY-1 (NCT07881432, obesity without diabetes, ~2,115 patients) and AMPLIFY-2 (NCT07881458, obesity/overweight with type 2 diabetes) are expected to begin enrollment around December 2026, but topline results are not expected until late 2029 at the earliest -- no near-term binary catalyst. Watch for the optimized co-formulation details and any updated dose-escalation regimens that could improve the tolerability profile before the Phase 3 program fully launches.

Bull case
  • Phase 2b data showed EloraTZP produced up to 23.3% average weight loss at 48 weeks, far exceeding tirzepatide 15 mg alone (14.8%), a highly competitive profile in the obesity market.
  • A1C reduction of up to 2.9% (vs 2.4% for tirzepatide) demonstrates meaningful additive glycemic benefit for patients with type 2 diabetes.
  • Lilly is rapidly advancing to Phase 3 with two registered trials (AMPLIFY-1 and AMPLIFY-2), signaling confidence in the data and the potential for a co-formulated product.
Bear case
  • Tolerability is a significant concern: discontinuation due to adverse events ranged from 10.8% to 27% across EloraTZP arms versus just 2.9% for tirzepatide alone, potentially limiting real-world adoption.
  • The Phase 2b data have not yet appeared in a peer-reviewed journal, and the topline results may be less compelling when full data are scrutinized.
  • Phase 3 trials will not read out until approximately October 2029, leaving years for competitors (Novo Nordisk's amycretin/zenagamtide and other amylin combos) to advance or capture market share.
◆ mixed
Impact
PhaseApproved (marketed in two indications); Phase 3 expansion trials ongoing
Time to marketAlready marketed: Mounjaro (type 2 diabetes) approved May 13, 2022; Zepbound (obesity) approved Nov 8, 2023. Expansion programs (cardiovascular outcomes, chronic kidney disease, type 1 diabetes with obesity) are in Phase 2/3 and years from any approval decision.

tirzepatide Updated Aug 18

What to watch

Watch for the SURPASS-CVOT cardiovascular-outcomes readout (trial recorded as COMPLETED as of July 2026, date unconfirmed) and any Zepbound label-expansion FDA decisions, plus Q3 earnings (expected early November 2026) for Mounjaro/Zepbound sales momentum vs. the raised $85–87B full-year guidance. The main investor question is no longer whether tirzepatide works, it is whether growth stays ahead of Novo Nordisk's next-gen competition (CagriSema head-to-head Phase 3 vs. tirzepatide is COMPLETED) and Lilly's own retatrutide, and whether the stock's near-all-time-high valuation leaves room for error.

Bull case
  • Explosive commercial scale: Q2 2026 Mounjaro revenue $9.9B (+91% YoY) and Zepbound $4.9B (+46%) drove Lilly to $22.97B total quarterly revenue (+48%) and a full-year guide raise from $82–85B to $85–87B (LLY 8-K filed 2026-08-05).
  • Two FDA approvals already secured, Mounjaro (2022-05-13) and Zepbound (2023-11-08), with label-expansion optionality: the SURPASS-CVOT cardiovascular-outcomes trial is Phase 3 COMPLETED, and Phase 3 type-1-diabetes/obesity plus Phase 2 CKD studies are active.
  • Sell-side support: analyst consensus shows 19 buy + 11 strong buy vs. 7 hold / 1 sell, with a mean price target of $1,310.90 (implied upside ~11.9% from $1,183.16 at observation); multiple firms raised targets in July–Aug 2026 (e.g., Citigroup to $1,600, RBC to $1,500).
Bear case
  • Competition is intensifying on both flanks: Novo Nordisk's head-to-head Phase 3 of CagriSema vs. tirzepatide in type 2 diabetes (NCT06534411) is COMPLETED, and Lilly's own next-gen retatrutide is advancing toward a BLA (Q1 2027 per the Q2 2026 earnings summary), a cannibalization risk to the tirzepatide franchise.
  • Compounding gray market and litigation: FDA Class II recalls of compounded 'tirzepatide' vials (New Life Pharma, Mar 2026, sterility concerns) and Lilly lawsuits against compounding pharmacies (Empower Clinic Services, Revive RX, Adonis Health) show channel-control and safety headaches beyond the branded drug.
  • Label safety overhang: 2026 FDA safety-labeling updates for both Mounjaro and Zepbound carry the thyroid C-cell tumor boxed-warning language (rodent finding), standard for the class but a perennial liability framing.
▲ bullish
Impact
PhaseApproved
Time to marketAlready launched. FDA approved September 2026; UK MHRA authorized October 2026. Commercial availability in the U.S. is underway.

Onswik insulin efsitora alfa Updated Oct 29

What to watch

With the FDA approval binary behind it, watch for commercial uptake metrics (prescription trends, formulary wins, payer coverage) in Lilly's quarterly reports, and for potential EU approval timing or a type 1 diabetes trial update. Onswik's market-share battle with Novo Nordisk's Awiqli is the key competitive dynamic to track over the next 12-18 months.

Bull case
  • Reduces annual insulin injections from ~365 to 52, a clear adherence and quality-of-life benefit that could drive adoption among injection-averse patients.
  • Phase 3 QWINT data demonstrated non-inferior glucose control versus widely used daily basal insulins (glargine, degludec) with comparable safety profiles in type 2 diabetes.
  • S&P Global consensus forecasts suggest efsitora could ultimately outsell Novo Nordisk's rival weekly insulin Awiqli longer term, despite being second to market.
Bear case
  • Novo Nordisk's Awiqli (insulin icodec) was FDA-approved in March 2026 and commercially launched in August 2026, giving it a roughly 6-month first-mover advantage in the U.S. once-weekly insulin category.
  • Onswik is not recommended for type 1 diabetes due to higher rates of severe hypoglycemia observed in trials, limiting the addressable patient population.
  • Pricing and formulary competition with Awiqli and cheap generic daily insulins could pressure margins; details on Lilly's U.S. launch pricing have not been prominent.

Other drugs in filings and trials

no drug report yet
  • Foundayo Last: Approval · Apr 30, 2026
  • Inluriyo Last: Approval · Oct 30, 2025
  • olomorasib Last: Breakthrough designation · Oct 30, 2025
  • EBGLYSS Last: Approval · Sep 13, 2024
  • KISUNLA Last: Approval · Jul 2, 2024
  • RETEVMO Last: Approval · Apr 10, 2024
  • OMVOH Last: Approval · Oct 26, 2023
  • REZVOGLAR Last: Approval · Nov 16, 2022
  • LYUMJEV Last: Approval · Jun 15, 2020
  • REYVOW Last: Approval · Oct 11, 2019
  • EMGALITY Last: Approval · Sep 27, 2018
  • OLUMIANT Last: Approval · May 31, 2018
  • VERZENIO Last: Approval · Feb 26, 2018
  • LARTRUVO Last: Approval · Oct 19, 2016
  • TALTZ Last: Approval · Mar 22, 2016 1 trial
  • BASAGLAR Last: Approval · Dec 16, 2015
  • PORTRAZZA Last: Approval · Nov 24, 2015
  • HUMALOG KWIKPEN Last: Approval · May 26, 2015
  • TRULICITY Last: Approval · Sep 18, 2014
  • CYRAMZA Last: Approval · Apr 21, 2014
  • Abemaciclib, 1 trial
  • Baricitinib 2 trials
  • Baricitinib 4 milligram Oral Tablet 1 trial
  • Lasmiditan 1 trial
  • Lebrikizumab 2 trials
  • LY3549492 1 trial
  • LY3848575 1 trial
  • LY3871801 1 trial
  • Mazdutide 1 trial
  • Mevidalen 1 trial
  • Mirikizumab 1 trial
  • Orforglipron 2 trials
  • Retatrutide 4 trials

Past FDA events & how the stock moved

26 events
DateDrugEvent1 day5 days
Apr 30, 2026FoundayoApproval+13.2%+14.5%
Apr 1, 2026FOUNDAYOApproval+1.7%+3.9%
Oct 30, 2025olomorasibBreakthrough designation+6.1%+15.2%
Oct 30, 2025InluriyoApproval+6.1%+15.2%
Sep 25, 2025INLURIYOApproval−2.3%+10.5%
Sep 13, 2024EBGLYSSApproval−1.2%−1.4%
Jul 2, 2024KISUNLAApproval−1.8%+2.8%
Apr 10, 2024RETEVMOApproval+0.3%−0.8%
Nov 8, 2023tirzepatideApproval−1.4%−1.7%
Oct 26, 2023OMVOHApproval−4.5%−1.1%
Nov 16, 2022REZVOGLARApproval+3.1%+3.4%
May 13, 2022tirzepatideApproval+2.9%+2.8%
Jun 15, 2020LYUMJEVApproval+14.1%+11.0%
May 8, 2020RETEVMOApproval+3.6%+4.6%
Oct 11, 2019REYVOWApproval+0.9%+1.6%
Sep 27, 2018EMGALITYApproval+0.9%+6.3%
May 31, 2018OLUMIANTApproval+1.2%+2.4%
Feb 26, 2018VERZENIOApproval−0.1%−1.3%
Sep 28, 2017VERZENIOApproval+1.1%+3.5%
Oct 19, 2016LARTRUVOApproval−0.0%−2.5%
Mar 22, 2016TALTZApproval+1.3%+2.2%
Dec 16, 2015BASAGLARApproval+0.8%+0.8%
Nov 24, 2015PORTRAZZAApproval−1.2%−0.2%
May 26, 2015HUMALOG KWIKPENApproval+0.8%+4.9%
Sep 18, 2014TRULICITYApproval+0.9%−0.5%
Apr 21, 2014CYRAMZAApproval−0.7%−2.4%

Clinical trials

40 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
MethylprednisolonePhase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)Phase 2Active not recruiting7Feb 2027
AbemaciclibA Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following RadiotherapyPhase 2Active not recruiting45Feb 2027
tirzepatideA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or OverweightPhase 3Active not recruiting905Nov 2026
tirzepatideA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or OverweightPhase 3Active not recruiting465Nov 2026
Baricitinib 4 milligram Oral TabletEfficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept StudyPhase 2Completed10Aug 12, 2026
RetatrutideEffect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)Phase 3Active not recruiting1,250Aug 2026
OrforglipronA Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightPhase 3Completed712Jul 21, 2026
tirzepatideA Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesPhase 2Completed134Jul 6, 2026
tirzepatideA Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 DiabetesPhase 2Completed367Jul 1, 2026
MirikizumabA Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)Phase 3Active not recruiting1,063Jul 2026
RetatrutideA Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightPhase 3Completed1,152Jun 16, 2026
tirzepatideEffects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIVPhase 2Completed12Jun 2, 2026
TaltzEffects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic StenosisPhase 2Completed10May 19, 2026
LebrikizumabA Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot DermatitisPhase 3Completed221May 13, 2026
RamucirumabRamucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaPhase 2Completed · results43May 11, 2026
MevidalenA Study of Mevidalen (LY3154207) in Participants With Alzheimer's DiseasePhase 2Completed304May 1, 2026
Mirikizumab IVA Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative ColitisPhase 3Completed63May 1, 2026
Abemaciclib,Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLCPhase 2Completed14Apr 30, 2026
BaricitinibBaricitinib for Central Centrifugal Cicatricial Alopecia in Adults of African DescentPhase 2Completed27Apr 28, 2026
LebrikizumabLong-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic DermatitisPhase 3Completed174Apr 23, 2026
RetatrutideA Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseasePhase 3Completed1,946Apr 16, 2026
tirzepatideWeekly GLP-1 Receptor Agonists in Obese Individuals Without DiabetesPhase 3Completed150Apr 13, 2026
RetatrutideA Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightPhase 3Completed2,335Apr 6, 2026
BaricitinibJanus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney DiseasePhase 2Completed8Apr 3, 2026
MazdutideA Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use DisorderPhase 2Completed308Mar 19, 2026
OrforglipronA Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskPhase 3Completed2,749Mar 16, 2026
FulvestrantEvaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial CancerPhase 2Completed · results27Mar 12, 2026
AbemaciclibA Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic CancerPhase 2Terminated · results6Mar 11, 2026
tirzepatideTirzepatide for Obesity and Meth Use DisorderPhase 2Completed35Feb 12, 2026
RetatrutideEffect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)Phase 3Completed537Jan 22, 2026
tirzepatideA Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesPhase 3Completed441Jan 20, 2026
LY3848575Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory PolyneuropathyPhase 2Completed558Jan 12, 2026
tirzepatideIxekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or OverweightPhase 3Completed281Jan 8, 2026
LY3549492A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or OverweightPhase 2Completed288Jan 7, 2026
tirzepatideA Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With ObesityPhase 2Completed392Dec 15, 2025
LY3871801An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid ArthritisPhase 2Completed164Dec 8, 2025
LasmiditanA 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With MigrainePhase 3Terminated · results558Dec 4, 2025
tirzepatideEffect of Tirzepatide on Brown Adipose Tissue in ObesityPhase 2Completed34Nov 29, 2025
OrforglipronA Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)Phase 3Completed376Nov 21, 2025
tirzepatideIxekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or OverweightPhase 3Completed279Nov 18, 2025